Clinical registration study on the efficacy and safety of the concept of intervention without implantation in the interventional treatment of patients with coronary heart disease

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100054749

Enrollment

Unknown

Registered

2021-12-26

Start date

2022-01-01

Completion date

Unknown

Last updated

2022-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary atherosclerotic heart disease

Interventions

Case series:Under went the concept of intervention without implantation in the interventional treatment of coronary heart disease patients

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. From January 2022 to December 2023, the hospital and the medical consortium of the hospital include Deqing County People's Hospital, Jiangshan People's Hospital, Longyou People's Hospital, Fuyang People's Hospital, Shangyu Traditional Chinese Medicine Hospital, Wuyi People's Hospital, Patients admitted to Wenzhou Central Hospital for coronary intervention; 2. Use of permanent stents or drug balloons or bioabsorbable stents during coronary intervention; 3. Receive regular outpatient or telephone follow-up after surgery; 4. Voluntarily participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Known contraindications or resistance to the following drugs: tirofiban, low molecular weight heparin, unfractionated heparin, aspirin/ticagrelor/clopidogrel; 2. Participate in other clinical studies and interfere with this study; 3. Known intracranial diseases such as mass, aneurysm, arteriovenous malformation, hemorrhagic cerebrovascular accident, ischemic cerebrovascular accident or transient ischemic attack (TIA) < 6 months or ischemic cerebral Vascular accident with permanent neurological deficit; 4. Gastrointestinal bleeding/urethral bleeding < 2 months; 5. Life expectancy < 36 months; 6. Patients with liver and renal failure; 7. Vulnerable groups, including people with mental illness, cognitive impairment, critically ill patients, minors, pregnant women, etc.

Design outcomes

Primary

Measure	Time frame
Major cardiovascular adverse events;	—

Secondary

Measure	Time frame
Nonfatal myocardial infarction;Cardiac death;Stroke;Revascularization;Stent thrombosis;	—

Countries

China

Contacts

Public ContactZhang Wenbin

Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine

3313011@zju.edu.cn+86 13777572567

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026